Meeting Report: American Urological Association (AUA) 2025

Key Points

AUA’s 2025 annual meeting was held April 26–29 in Las Vegas, Nevada.
Principal investigators presented clinical data from studies sponsored by Profound Medical and EDAP.

The American Urological Association (AUA) held its annual meeting from April 26–29, 2025, in Las Vegas, Nevada. AUA supports the urological community through education, research, and the formulation of health care policy.

Principal investigators presented clinical data from studies sponsored by Profound Medical and EDAP/Focal One during the conference.

For EDAP/Focal One, the Focal Ablation Versus Radical Prostatectomy (FARP) Study was presented by principal investigator Eduard Baco, MD, PhD, associate professor of Cancer Surgery at Oslo University Hospital. FARP is the first randomized controlled trial to compare outcomes from focal ablation with robotic prostatectomy. After 36 months of follow up, the rate of treatment failure in the focal ablation group was found to be non-inferior to that in the radical prostatectomy group. Notably, the FARP study included focal ablation data from two different approaches to the prostate: EDAP’s Focal One transrectal high-intensity focused ultrasound (HIFU) system, and Profound Medical’s transurethral ultrasound ablation (TULSA) TULSA-PRO system. (See Abstract PD19-01 below.)

For Profound Medical, Xiaosong Meng, MD, PhD, assistant professor of urology at UT Southwestern Medical Center, presented positive initial perioperative data from the Level 1 post-market CAPTAIN trial, which is comparing the safety and efficacy of the TULSA-PRO procedure with radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. TULSA provided statistically significant improvement in all assessed perioperative measures, including blood loss, length of stay, pain, and patient-reported, health-related quality of life measures. (See Abstract PD19-07 below.)

AUA 2025 featured 22 abstracts and data from several clinical trials that may be of interest to the focused ultrasound community. Each abstract has been published in the Journal of Urology and can be found by searching the AUA 2025 supplemental issue for “HIFU,” “focused ultrasound,” “TULSA,” or your own key words.

Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I (IP03) (1)

IP03-40 Evaluating the Safety and Efficacy of En-Bloc Holmium Laser Enucleation of the Prostate in Patients with a History of Radiation Therapy or High Frequency Focused Ultrasound for Management of Organ Confined Prostate Cancer

Imaging/Uroradiology (IP22) (1)

IP22-13 Age-Stratified Evaluation of Oncological and Functional Outcomes of Focal Therapy with High-Intensity Focused Ultrasound for Patients with Localized Prostate Cancer: A Multi-Institutional Prospective Study in Japan

Prostate Cancer: Advanced (Including Drug Therapy) III (IP26) (1)

IP26-35 Novel Cytoreductive Prostate Ablative Therapies in De Novo Metastatic Prostate Cancer: Lessons Learnt from A Phase II Internal Pilot Randomised Study (IP2-ATLANTA)

Prostate Cancer: Localized: Ablative Therapy I (MP04) (11)

MP04-02 MRI-Guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: Single Institution Experience of Treatment Efficacy

MP04-04 Prognostic Value of PSA Kinetics Following High-Intensity Focused Ultrasound In Focal Therapy for Localized Prostate Cancer: A Single-Center Prospective Study

MP04-05 Early Outcomes of Multi-Imaging Guided High-Intensity Focused Ultrasound for Localized Prostate Cancer: Update from a Large Single-Center Cohort

MP04-06 Evaluating Patient-Reported Outcomes in Focal Therapy for Localized Prostate Cancer: Three-Year Update on Clinical Experience with High-Intensity Focused Ultrasound

MP04-07 Erectile Function Outcomes Following High-Intensity Focused Ultrasound for Prostate Cancer